Operating on DNA is more like surgery than medicine

TLDR

• A16z argues gene editing is fundamentally a surgical intervention on specific sequences, not a systemic drug treatment.

Key Takeaways

• The surgery-vs-medicine framing reframes how practitioners should think about precision, targeting, and reversibility in DNA interventions.
• Unlike drugs that circulate systemically, DNA edits act at discrete genomic locations, with implications for dosing, delivery, and error tolerance.
• The distinction shapes how builders and investors should evaluate risk, regulatory pathways, and therapeutic design in genomics.
• Framing gene editing as surgery implies higher standards for accuracy and consent, not just efficacy benchmarks.

Why It Matters

• Regulatory and clinical frameworks built for drugs may be poorly matched to the precision requirements of genomic interventions.
• Founders and operators building in genomics need to design products and trials around a surgery mental model, not a pharmaceutical one.
• The framing has downstream effects on liability, reversibility expectations, and how failure modes are defined and disclosed.

Andreessen Horowitz · 2026-01-28 · Read the original